The clinical significance of hypoxia in human cancers

Seminars in Nuclear Medicine

Volumn 45, Issue 2, 2015, Pages 110-121

  Dhani, Neesha ^a,b   Fyles, Anthony ^a,b   Hedley, David ^a,b   Milosevic, Michael ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CLINICAL PRACTICE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; METASTASIS; NEOPLASM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PANCREAS CANCER; PROSTATE CANCER; TREATMENT RESPONSE; UTERINE CERVIX CANCER; CELL HYPOXIA; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

CELL HYPOXIA; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84924072763     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2014.11.002     Document Type: Review

References (58)

1. S. Jones, X. Zhang, and D.W. Parsons Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 2008 1801 1806
2. T.G. Graeber, C. Osmanian, and T. Jacks Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors Nature 379 1996 88 91
3. C.Y. Kim, M.H. Tsai, and C. Osmanian Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions Cancer Res 57 1997 4200 4204
4. R.G. Bristow, A. Berlin, and A. Dal Pra An arranged marriage for precision medicine: Hypoxia and genomic assays in localized prostate cancer radiotherapy Br J Radiol 87 2014 20130753
5. P. Vaupel, F. Kallinowski, and P. Okunieff Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review Cancer Res 49 1989 6449 6465
6. M. Hockel, and P. Vaupel Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 2001 266 276
7. A. Carreau, B. El Hafny-Rahbi, and A. Matejuk Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia J Cell Mol Med 15 2011 1239 1253
8. J.M. Brown, and W.R. Wilson Exploiting tumour hypoxia in cancer treatment Nat Rev Cancer 4 2004 437 447
9. W.R. Wilson, and M.P. Hay Targeting hypoxia in cancer therapy Nat Rev Cancer 11 2011 393 410
10. L.J. Peters, B. OSullivan, and J. Giralt Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results from TROG 02.02. J Clin Oncol 28 2010 2996 3001
11. N. Dhani, and M. Milosevic Targeting tumoral hypoxia: Finding opportunity in complexity Future Oncol 8 2012 1065 1068
12. A. Fyles, M. Milosevic, and D. Hedley Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer J Clin Oncol 20 2002 680 687
13. M. Nordsmark, S.M. Bentzen, and V. Rudat Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study Radiother Oncol 77 2005 18 24
14. M. Nordsmark, and J. Overgaard A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy Radiother Oncol 57 2000 39 43
15. A. Fyles, M. Milosevic, and M. Pintilie Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer Radiother Oncol 80 2006 132 137
16. M. Hockel, K. Schlenger, and S. Hockel Hypoxic cervical cancers with low apoptotic index are highly aggressive Cancer Res 59 1999 4525 4528
17. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix Radiother Oncol 53 2 1999 99 104
18. H. Lyng, K. Sundfor, and C. Trope Disease control of uterine cervical cancer: Relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy Clin Cancer Res 6 2000 1104 1112
19. M. Hockel, K. Schlenger, and B. Aral Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 1996 4509 4515
20. R.A. Cairns, R. Khokha, and R.P. Hill Molecular mechanisms of tumor invasion and metastasis: An integrated view Curr Mol Med 3 2003 659 671
21. M.I. Koukourakis, S.M. Bentzen, and A. Giatromanolaki Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial J Clin Oncol 24 2006 727 735
22. H.K. Haugland, V. Vukovic, and M. Pintilie Expression of hypoxia-inducible factor-1α in cervical carcinomas: Correlation with tumor oxygenation Int J Radiat Oncol Biol Phys 53 2002 854 861
23. D. Hedley, M. Pintilie, and J. Woo Carbonic anhydrase IX expression, hypoxia and prognosis in patients with invasive uterine cervical carcinomas Clin Cancer Res 15 2003 5666 5674
24. V.V. Iakovlev, M. Pintilie, and A. Morrison Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX Lab Invest 87 2007 1206 1217
25. G.L. Semenza HIF-1: Upstream and downstream of cancer metabolism Curr Opin Genet Dev 20 2010 51 56
26. K. Toustrup, B.S. Sorensen, and M. Nordsmark Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer Cancer Res 71 2011 5923 5931
27. K. Toustrup, B.S. Sorensen, and P. Lassen Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck Radiother Oncol 102 2012 122 129
28. C. Halle, E. Andersen, and M. Lando Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI Cancer Res 72 2012 5285 5295
29. L.S. Mortensen, J. Johansen, and J. Kallehauge FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial Radiother Oncol 105 2012 14 20
30. D. Zips, K. Zöphel, and N. Abolmaali Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer Radiother Oncol 105 2012 21 28
31. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2006 2098 2104
32. J. Overgaard Hypoxic radiosensitization: Adored and ignored J Clin Oncol 25 2007 4066 4074
33. J. Overgaard Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck - A systematic review and meta-analysis Radiother Oncol 100 2011 22 32
34. J. Overgaard, H.S. Hansen, and M. Overgaard A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 Radiother Oncol 46 1998 135 146
35. D. Rischin, L.J. Peters, and B. OSullivan Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group J Clin Oncol 28 2010 2989 2995
36. M.L. Gillison, G. DSouza, and W. Westra Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers J Natl Cancer Inst 100 2008 407 420
37. P. Lassen, J.G. Eriksen, and S. Hamilton-Dutoit Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck J Clin Oncol 27 2009 1992 1998
38. D. Rischin, R.J. Young, and R. Fisher Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial J Clin Oncol 28 2010 4142 4148
39. R. Siegel, J. Ma, and Z. Zou Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
40. D.A. Kuban, L.B. Levy, and M.R. Cheung Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79 2011 1310 1317
41. M. Milosevic, P. Warde, and C. Menard Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer Clin Cancer Res 18 2012 2108 2114
42. R. Vergis, C.M. Corbishley, and A.R. Norman Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study Lancet Oncol 9 2008 342 351
43. M.W. Dewhirst, Y. Cao, and B. Moeller Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response Nat Rev Cancer 8 2008 425 437
44. N.J. Mabjeesh, M.T. Willard, and C.E. Frederickson Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells Clin Cancer Res 9 2003 2416 2425
45. D. Taiakina, A. Dal Pra, and R.G. Bristow Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer Adv Exp Med Biol 772 2014 189 204
46. R. Bristow, E. Lalonde, and M. Milosevic Complementarity of genomic instability and hypoxia indices for predicting prostate cancer recurrence Radiother Oncol 111 2014 65
47. L.G. Smyth, G. OHurley, and A. OGrady Carbonic anhydrase IX expression in prostate cancer Prostate Cancer Prostatic Dis 13 2010 178 181
48. D.M. Carnell, R.E. Smith, and F.M. Daley An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance Int J Radiat Oncol Biol Phys 65 2006 91 99
49. 18F]fluoromisonidazole: A pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 1996 417 428
50. 18F-FAZA PET/CT utilizing multimodality fusion techniques Eur J Nucl Med Mol Imaging 38 2011 1816 1823
51. P.P. Provenzano, and S.R. Hingorani Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer Br J Cancer 108 2013 1 8
52. G. Gortenuti, G. Cavallini, and I. Vantini Angiography in chronic pancreatitis and pancreatic cancer. A critical evaluation Am J Gastroenterol 70 1978 620 626
53. G. Komar, S. Kauhanen, and K. Liukko Decreased blood flow with increased metabolic activity: A novel sign of pancreatic tumor aggressiveness Clin Cancer Res 15 2009 5511 5517
54. A.C. Koong, V.K. Mehta, and Q.T. Le Pancreatic tumors show high levels of hypoxia Int J Radiat Oncol Biol Phys 48 2000 919 922
55. P. Buchler, H.A. Reber, and M. Buchler Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer Pancreas 26 2003 56 64
56. M.W. Moyer Targeting hypoxia brings breath of fresh air to cancer therapy Nat Med 18 2012 636 637
57. M. Hidalgo, F. Amant, and A.V. Biankin Patient-derived xenograft models: An emerging platform for translational cancer research Cancer Discov 4 2014 998 1013
58. Q. Chang, I. Jurisica, and T. Do Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer Cancer Res 71 2011 3110 3120